$NUKK
Nukkleus Inc. Stock $nukk

$nukk Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023041976 Filed on May 22, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$5.370M	$5.486M	$5.415M
YoY Change	-1.03%	1.31%	14.61%
Gross Profit	-$158.0K	$148.0K	-$326.2K
YoY Change	-42.23%	-145.36%	-534.88%
Gross Profit Margin
Selling, General & Admin	$988.5K	$888.0K	$1.461M
YoY Change	-24.81%	-39.23%	1889.75%
% of Gross Profit		600.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$592.9K	$1.186M	$1.505M
YoY Change	0.0%	-21.2%
% of Gross Profit		801.42%
Operating Expenses	$120.0K	$78.38K	$469.3K
YoY Change	-17.01%	-83.3%	498.48%
Operating Profit	-$123.7K	-$78.38K	-$469.3K
YoY Change	-14.41%	-83.3%	13661.61%
Interest Expense	$0.00	-$930.00	$8.990K
YoY Change	-100.0%	-110.34%	-84.51%
% of Operating Profit
Other Income/Expense, Net	$1.385K	-$925.00	$8.989K
YoY Change	-98.73%	-110.29%	-1677.02%
Pretax Income	-$120.0K	-$79.31K	-$460.3K
YoY Change	237.65%	-82.77%	2159.6%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$122.4K	-$79.31K	-$460.3K
YoY Change	244.26%	-82.77%	2159.27%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.06	-$0.04	-$0.08
Diluted Earnings Per Share	-$0.06	-$0.04	-$76.20K
COMMON SHARES
Basic Shares Outstanding	1.816M shares	1.817M shares	6.041M shares
Diluted Shares Outstanding	1.916M shares	1.949M shares	6.041M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.597M	$4.464M	$41.65M
YoY Change	-88.95%	-89.28%	-10.68%
Cash & Equivalents	$4.597M	$4.464M	$154.3K
Short-Term Investments			$41.50M
Other Short-Term Assets	$0.00	$740.00	$154.5K
YoY Change	-100.0%	-99.52%	440.79%
Inventory
Prepaid Expenses
Receivables	$189.2K	$189.2K	$55.89K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.597M	$4.464M	$41.81M
YoY Change	-88.97%	-89.32%	-10.4%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$6.602M	$6.602M	$11.53M
YoY Change	-41.06%	-42.75%
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$4.597M	$4.464M	$41.81M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$4.597M	$4.464M	$41.81M
YoY Change	-88.97%	-89.32%	-10.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$470.0K	$286.2K	$234.1K
YoY Change	316.29%	22.28%	621.55%
Accrued Expenses	$450.2K	$579.7K	$451.5K
YoY Change	-2.66%	28.41%	675.04%
Deferred Revenue
YoY Change
Short-Term Debt	$4.030M	$3.817M	$2.830M
YoY Change	37.54%	34.88%	1060.66%
Long-Term Debt Due		$17.50K
YoY Change
Total Short-Term Liabilities	$4.504M	$4.103M	$3.064M
YoY Change	48.01%	33.92%	815.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.00K	$11.57K	$175.4K
YoY Change	-91.6%	-93.41%	-8.02%
Total Long-Term Liabilities	$10.00K	$11.57K	$175.4K
YoY Change	-91.6%	-93.41%	-8.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.504M	$4.103M	$3.064M
Total Long-Term Liabilities	$10.00K	$11.57K	$175.4K
Total Liabilities	$4.514M	$4.115M	$3.240M
YoY Change	42.76%	27.02%	516.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.327M	-$7.966M
YoY Change	20.69%
Common Stock	$3.880M	$3.880M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.447M	-$4.086M	-$2.931M
YoY Change
Total Liabilities & Shareholders Equity	$4.597M	$4.464M	$41.81M
YoY Change	-88.97%	-89.32%	-10.4%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$122.4K	-$79.31K	-$460.3K
YoY Change	244.26%	-82.77%	2159.27%
Depreciation, Depletion And Amortization	$592.9K	$1.186M	$1.505M
YoY Change	0.0%	-21.2%
Cash From Operating Activities	-$70.00K	-$107.2K	-$699.3K
YoY Change	-67.37%	-84.67%	714.41%
INVESTING ACTIVITIES
Capital Expenditures	$460.00	$41.25K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$5.895M
YoY Change		-100.0%
Cash From Investing Activities	$0.00	$0.00	$5.895M
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	210.0K	-$1.540M	-5.325M
YoY Change	110.0%	-71.08%
NET CHANGE
Cash From Operating Activities	-70.00K	-$107.2K	-699.3K
Cash From Investing Activities	0.000	0.000	5.895M
Cash From Financing Activities	210.0K	-$1.540M	-5.325M
Net Change In Cash	140.0K	-$1.647M	-129.2K
YoY Change	-222.25%	1175.39%
FREE CASH FLOW
Cash From Operating Activities	-$70.00K	-$107.2K	-$699.3K
Capital Expenditures	$460.00	$41.25K
Free Cash Flow	-$70.46K	-$148.4K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1948973	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6040579	shares
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39341
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Floor 20-21
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	No. 55 Loushanguan Road
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	Changning District
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Shanghai
CY2023Q1	dei	Entity Address Country EntityAddressCountry	CN
CY2023Q1	dei	City Area Code CityAreaCode	(86)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	021-80125497
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1816475	shares
CY2023Q1	us-gaap	Cash Cash	4463639	usd
CY2022Q4	us-gaap	Cash Cash	6110807	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	738	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	738	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	4464377	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6111545	usd
CY2023Q1	us-gaap	Assets Assets	4464377	usd
CY2022Q4	us-gaap	Assets Assets	6111545	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	286232	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	315023	usd
CY2023Q1	brli	Due To Related Party DueToRelatedParty	1050600	usd
CY2022Q4	brli	Due To Related Party DueToRelatedParty	970600	usd
CY2023Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	2766577	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	2680227	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4103409	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3965850	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	11568	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10643	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4114977	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3976493	usd
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	405733	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	564936	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4435020	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	6055016	usd
CY2022Q4	brli	Preferred Stock Shares Authorized Unlimited Shares PreferredStockSharesAuthorizedUnlimitedShares	unlimited
CY2023Q1	brli	Preferred Stock Shares Authorized Unlimited Shares PreferredStockSharesAuthorizedUnlimitedShares	unlimited
CY2022Q4	brli	Common Stock Shares Authorized Unlimited Share CommonStockSharesAuthorizedUnlimitedShare	unlimited
CY2023Q1	brli	Common Stock Shares Authorized Unlimited Share CommonStockSharesAuthorizedUnlimitedShare	unlimited
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1511000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1511000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3880288	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3880288	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7965908	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7800252	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4085620	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3919964	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4464377	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6111545	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	78381	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	469271	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-78381	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-469271	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	925	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5041	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	3948	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-925	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8989	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-79306	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-460282	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1948973	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6040579	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-452006	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-3948	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-460282	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-916236	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3919964	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-79306	usd
CY2023Q1	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-86350	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4085620	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-79306	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-460282	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	925	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-5041	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-28791	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-75527	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-107171	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-699248	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	634594	usd
CY2022Q1	brli	Proceeds From Sale Of Investment Of Cash In Trust Account ProceedsFromSaleOfInvestmentOfCashInTrustAccount	6529259	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5894665	usd
CY2023Q1	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	80000	usd
CY2022Q1	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	570100	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	86350	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	634594	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	1706347	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	6529259	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1539997	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5324565	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1647168	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-129148	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6110807	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	283403	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4463639	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154255	usd
CY2023Q1	brli	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	86350	usd
CY2022Q1	brli	Remeasurement Adjustment Of Ordinary Shares To Redemption Value RemeasurementAdjustmentOfOrdinarySharesToRedemptionValue	638542	usd
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10
CY2020Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P180D
CY2023Q1	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2069154	usd
CY2023Q1	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	1610000	usd
CY2023Q1	brli	Other Offering Cost OtherOfferingCost	459154	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	28618	usd
CY2023Q1	brli	Fair Market Value Percentage FairMarketValuePercentage	0.80	pure
CY2023Q1	brli	Additional Price Per Share AdditionalPricePerShare	0.16
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.1
CY2021Q2	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2021Q3	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	460000	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	633792	shares
CY2022Q1	brli	Aggregate Amounts AggregateAmounts	6529259	usd
CY2022Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.3
CY2022Q1	us-gaap	Deposit Assets DepositAssets	101406	usd
CY2022Q1	brli	Aggregate Amounts AggregateAmounts	633792	usd
CY2022Q3	brli	Aggregate Amount Shares AggregateAmountShares	1025281	shares
CY2022Q3	brli	Aggregate Amounts AggregateAmounts	10742906	usd
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.48
CY2022Q4	brli	Public Ordinary Per Share PublicOrdinaryPerShare	0.04
CY2022Q4	us-gaap	Deposit Assets DepositAssets	22600	usd
CY2022Q4	brli	Aggregate Amount Shares AggregateAmountShares	2375991	shares
CY2022Q4	brli	Aggregate Amounts AggregateAmounts	25180851	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.6
CY2022Q4	brli	Description Of Deposite DescriptionOfDeposite	On November 18, 2022, Nukkleus deposited $22,600 into the Trust Account, representing $0.04 per public ordinary share that was not redeemed in connection with extending the business combination completion window until November 23, 2022. On December 19, 2022, Nukkleus deposited $22,600 into the Trust Account, representing $0.04 per public ordinary share that was not redeemed in connection with extending the business combination completion window until January 23, 2023. On January 19, 2023, the shareholders of the Company approved the extension of the period of time the Company has to consummate its initial business combination from January 23, 2023 to up to not later than April 23, 2023, extendable by the Company on a monthly basis without further shareholder approval upon deposit of $0.04 per public ordinary share of the Company (the “Top-up Amount”). Notwithstanding the Top-up Amount, the Company undertook to increase the amount to be paid into the Trust Account for each monthly extension from $0.04 to $0.0525. Subsequently, the Company has committed to increase the amount to be paid into the Trust Account for any extension from February 23, 2023 to March 23, 2023 and from March 23, 2023 to April 23, 2023 to $0.08 per ordinary share outstanding. In connection with the extension, Nukkleus deposited $21,350 into the Trust Account, representing $0.0525 per public ordinary share that was not redeemed in connection with extending the business combination completion window until February 23, 2023. In connection with a special meeting to approve the extension of the business combination period, the Company’s shareholders elected to redeem an aggregate amount of 159,203 shares, and the Company redeemed such shares for an aggregate amount of $1,706,347, or approximately $10.72 per share
CY2023Q1	us-gaap	Deposit Assets DepositAssets	32500	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q2	us-gaap	Deposit Assets DepositAssets	32450	usd
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.08
CY2023Q1	brli	Aggregate Amount Shares AggregateAmountShares	258	shares
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2820	usd
CY2023Q1	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
	brli	Redeemption Percent RedeemptionPercent	1	pure
	us-gaap	Other Expenses OtherExpenses	50000	usd
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28618	usd
CY2022Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	1307476	usd
CY2022Q3	brli	Trust Account TrustAccount	32450	usd
CY2023Q1	brli	Description Of Trust Account DescriptionOfTrustAccount	which is before May 23, 2023 (or July 23, 2023 if further extended by placing $32,450 into the Trust Account).
CY2023Q1	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	4435020	usd
CY2023Q1	brli	Registration Rights Description RegistrationRightsDescription	Notwithstanding the foregoing, EarlyBirdCapital, Inc. (“EarlyBirdCapital”) may not exercise its demand and “piggyback” registration rights after five (5) and seven (7) years after the effective date of the registration statement and may not exercise its demand rights on more than one occasion. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	brli	Cash And Noncash Equivalents CashAndNoncashEquivalents	28618	usd
CY2022	brli	Cash And Noncash Equivalents CashAndNoncashEquivalents	55789	usd
CY2022Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	633792	shares
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1025281	shares
CY2022Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	2375991	shares
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	159203	shares
CY2023Q1	brli	Subject To Possible Redemption SubjectToPossibleRedemption	405733	shares
CY2022	brli	Subject To Possible Redemption SubjectToPossibleRedemption	564936	shares
CY2023Q1	brli	Common Stock Per Share CommonStockPerShare	10
CY2021Q4	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	47387687	usd
CY2022	brli	Redemption Of Share RedemptionOfShare	633792	shares
CY2022	brli	Less Redemption Of Shares LessRedemptionOfShares	6529259	shares
CY2022	brli	Redemption Of Share1 RedemptionOfShare1	1025281	shares
CY2022	brli	Less Redemption Of Shares1 LessRedemptionOfShares1	10742905	shares
CY2022	brli	Redemption Of Share2 RedemptionOfShare2	2375991	shares
CY2022	brli	Less Redemption Of Shares2 LessRedemptionOfShares2	-25180851	shares
CY2022	brli	Add Accretion Of Carrying Value To Redemption Value AddAccretionOfCarryingValueToRedemptionValue	64950	shares
CY2022	brli	Reclassification Of Temporary Equity ReclassificationOfTemporaryEquity	1055394	shares
CY2022Q4	brli	Ordinary Shares Subject To Possible Redemption1 OrdinarySharesSubjectToPossibleRedemption1	6055016	usd
CY2023Q1	brli	Redemption Of Share3 RedemptionOfShare3	159203	shares
CY2023Q1	brli	Less Redemption Of Shares3 LessRedemptionOfShares3	-1706346	shares
CY2023Q1	brli	Reclassifications Of Temporary To Permanent Equity1 ReclassificationsOfTemporaryToPermanentEquity1	86350	shares
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-79306	usd
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-460282	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1948973	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6040579	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2022Q1	brli	Aggregate Of Shares AggregateOfShares	633792	shares
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2820	usd
CY2023Q1	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
CY2023Q1	brli	Working Capital WorkingCapital	1050600	usd
CY2023Q1	us-gaap	Direct Operating Costs DirectOperatingCosts	80000	usd
CY2023Q1	brli	Cash Fee Equal Percentage CashFeeEqualPercentage	0.01	pure
CY2023Q1	us-gaap	Business Combination Control Obtained Description BusinessCombinationControlObtainedDescription	The initial shareholders have agreed not to transfer, assign or sell any of the Founder Shares (except to certain permitted transferees) until the earlier of (i) one year after the date of the consummation of a Business Combination, or (ii) the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after a Business Combination, upon six months after the date of the consummation of a Business Combination, or earlier, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property.
CY2023Q1	brli	Public Per Share Outstanding PublicPerShareOutstanding	0.04
CY2021Q4	brli	Trust Account Management Expense TrustAccountManagementExpense	1000	usd
CY2022Q1	brli	Trust Account Management Expense TrustAccountManagementExpense	500	usd
CY2020Q2	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	261000	shares
CY2023Q1	us-gaap	Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1	925	usd
CY2022Q1	us-gaap	Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1	5041	usd
CY2023Q1	brli	Volatility Volatility	0.0323	pure
CY2022	brli	Volatility Volatility	0.034	pure
CY2023Q1	us-gaap	Share Price SharePrice	10.98
CY2022Q4	us-gaap	Share Price SharePrice	10.72
CY2023Q1	brli	Expected Life Of The Warrants To Converts ExpectedLifeOfTheWarrantsToConverts	P5Y3M21D
CY2022	brli	Expected Life Of The Warrants To Converts ExpectedLifeOfTheWarrantsToConverts	P5Y2M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0364	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0404	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	180479	usd
CY2022Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-5041	usd
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	175438	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10643	usd
CY2023Q1	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	925	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	11568	usd
CY2022Q3	us-gaap	Deposits Deposits	0.08	usd
CY2023Q1	brli	Aggregate Amount Shares AggregateAmountShares	258	shares
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2820	usd
CY2023Q1	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	10.93
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Brilliant Acquisition Corp
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities		usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	000000
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001787518

Files In Submission

Name	View Source	Status
brli-20230331_def.xml	Edgar Link	unprocessable
brli-20230331_cal.xml	Edgar Link	unprocessable
0001213900-23-041976-index-headers.html	Edgar Link	pending
0001213900-23-041976-index.html	Edgar Link	pending
0001213900-23-041976.txt	Edgar Link	pending
0001213900-23-041976-xbrl.zip	Edgar Link	pending
brli-20230331.xsd	Edgar Link	pending
f10q0323ex31-1_brilliantacq.htm	Edgar Link	pending
f10q0323ex31-2_brilliantacq.htm	Edgar Link	pending
f10q0323ex32-1_brilliantacq.htm	Edgar Link	pending
f10q0323_brilliant.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
brli-20230331_pre.xml	Edgar Link	unprocessable
brli-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_brilliant_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NUKK
Nukkleus Inc. Stock $nukk

2023 Q2 Form 10-Q Financial Statement

#000121390023041976 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUKK Nukkleus Inc. Stock $nukk

2023 Q2 Form 10-Q Financial Statement

#000121390023041976 Filed on May 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUKK
Nukkleus Inc. Stock $nukk